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Abstract
Background: Hemicrania continua is a strictly unilateral, continuous headache, typically mild to moderate in severity,
with severe exacerbations commonly accompanied by cranial autonomic features and migrainous symptoms. It is
exquisitely responsive to Indomethacin. However, some patients cannot tolerate treatment, often due to
gastrointestinal side effects. Therapeutic alternatives are limited and controlled evidence lacking.
Methods: We present our experience of nine patients treated with OnabotulinumtoxinA for hemicrania
continua. All patients were injected using the PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis
Therapy) protocol for migraine.
Results: Five of nine patients demonstrated a 50% or more r e d u c t i o ni nm o d e r a t et os e v e r eh e a d a c h ed a y s
with OnabotulinumtoxinA with a median reduction in moderate to severe headache days of 80%. Patient
estimate of response was 80% or more in five subjects. The median and mean duration of response in the five
responders was 11 and 12 weeks (range 6–20 weeks). Improvements were also seen in headache-associated disability
Conclusions: OnabotulinumtoxinA adds a potential option to the limited therapeutic alternatives available in
hemicrania continua.
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Background
Hemicrania continua (HC) is a strictly unilateral, con-
tinuous headache that is exquisitely responsive to Indo-
methacin [1]. It is more prevalent in women and usually
begins in adulthood [2,3]. The pain is typically of mild to
moderate intensity and often involves the forehead, tem-
poral, orbital and occipital regions [3]. Exacerbations of
pain are seen in the majority and are commonly accom-
panied by cranial autonomic features and migrainous
symptoms [2,3].
Hemicrania continua is, by definition, exquisitely re-
sponsive to Indomethacin [1]. Despite the efficacy of
Indomethacin in HC, more than 30% of patients experi-
ence adverse effects and 20% have to discontinue the drug
[4]. Finding possible therapeutic alternatives to Indometh-
acin is, thus, of great clinical relevance.
Several other drugs have been reported to be at
least partially effective in open-label reports including:
cyclooxygenase-2 inhibitors, aspirin, ibuprofen, naproxen,
topiramate, melatonin, valproic acid, gabapentin, verapamil
and methylprednisolone. Other options are greater occipi-
tal nerve blocks (GONB) and neuromodulation. However,
none appear to be as effective as Indomethacin.
Even though the exact mechanism of action of
OnabotulinumtoxinA (BoNT-A) remains unclear, it is
thought to involve multiple mechanisms. Theories include
inhibition of neurotransmitter release from motor and
sensory nociceptive neurons resulting in interruption of
the inflammatory loop promoting peripheral and central
sensitization or direct inhibition of central sensitization in
the CNS, via axonal transport [5].
The efficacy of BoNT-A in chronic migraine prophy-
laxis is now well established [6]. Experience in trigeminal
autonomic cephalalgias (TACs) is scarce; experience in
14 cluster headache and one Short-lasting Unilateral
Neuralgiform Headache with Conjunctival Injection and
Tearing (SUNCT) patients have been published [7-11].
In HC, there are two single subject case reports on the
use of BoNT-A [12,13]. In the first case, painless
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autonomic features fully resolved. In this open label study
we examine the outcome of nine patients undergoing
BoNT-A treatment for HC.
Methods
Patients receiving BoNT-A with the Headache Group at
the National Hospital for Neurology and Neurosurgery
were analyzed. Patients were diagnosed with HC in ac-
cordance to International Classification of Headache
Disorder criteria (ICHD-3beta) [1]. All had unilateral
headaches that had responded fully to an indomethacin
trial (oral or intramuscular trials, detailed in Table 1).
All patients were injected with BoNT-A as per the Phase
3 REsearch Evaluating Migraine Prophylaxis Therapy
(PREEMPT) regime for chronic migraine, with patients
having a modified regime (exclusion of occipital and cer-
vical paraspinal sites) if they had an occipital nerve stimu-
lator (ONS) in situ [6].
All data was collected prospectively with the use of
headache diaries. Average monthly scores were calculated
from a month pre-treatment and a three-month post-final
treatment diary. Headache days were recorded as any day
on which the subject recorded HC pain. Subjects were
asked to score pain intensity on two scales: 1) pain free,
mild, moderate and severe; and 2) verbal rating scale
(VRS). Headache load (HAL) was calculated from diaries
using the formula: ∑ (severity (VRS) × pain duration
(hours). Disability scores consisting of Headache Impact
Test (HIT-6), Migraine Disability Assessment (MIDAS)
and Hospital Anxiety and Depression scale (HAD) were
collected before and after treatment.
Responders to treatment were classified as those achiev-
ing a 50% or greater improvement in headache days rated
as moderate to severe. Other outcomes included those
achieving a 30% and 50% or greater improvement in HAL
and 30% or more improvement in headache days rated as
moderate to severe.
Median values pre- and post-treatment were compared
using Wilcoxon Signed Ranks tests and a statistically
significant result set at the 95% level (p=0.05). Data was
processed using IBM SPSS Version 22 for Windows.
The study was approved by Northwick Park Hospital
Research Ethics Committee, Hampstead, London, and
written consent obtained from all patients.
Results
A total of nine patients with HC received treatment with
BoNT-A, of whom six were females and three males (see
Table 1). Median age at time of treatment was 48 years
(19–61 years) and median duration of HC was 8 years
(1–34 years). During exacerbations, migrainous features
were present in six and autonomic features in all subjects.
Three patients reported visual auras during exacerbations.
Four patients had concomitant episodic migraine (EM)
and one co-existent idiopathic stabbing headache. All
patients were able to differentiate their co-existent head-
aches from HC and none of the co-existent headaches had
responded to indomethacin trials.
Subjects had failed to respond to a median of seven pre-
vious treatments for HC. Two subjects had failed to re-
spond to ONS and one was awaiting ONS implantation.
Reasons for treatment with BoNT-A are summarized
in Table 1. Eight patients could not tolerate therapeutic
doses of indomethacin due to gastro-intestinal (GI) side
effects. Two patients complained of worsening of their
EM with indomethacin doses required to suppress HC.
Patients had a median of two treatments (range 2–6) with
a median BoNT-A dose of 167 units (range 110–185
units) injected at each treatment.
The results of BoNT-A treatment are summarized in
Table 2. Five subjects demonstrated a response of 50%
or more in reduction of moderate or severe headache
days to mild headache days or pain free and were classi-
fied as responders to treatment. Six subjects reported a
30% or greater response in reduction of moderate or se-
vere headache days to mild headache days or pain free.
The median reduction in total headache days was 90%
(range 0–100) (p=0.026) and in moderate to severe
headache days 80% (range 0–100) (p=0.012). Headache
load showed a median improvement of 62% (range 0–100)
with six patients demonstrating a 30% and 50% or more
improvement. Significant improvements were also seen in
average headache hours and average VRS (Table 2). The
median subjective duration of response in the five re-
sponders post treatment was 11 weeks (range 6–20 weeks,
mean 12 weeks). Five subjects reported a subjective bene-
fit of 80% or more in their HC.
Four subjects were taking indomethacin prior to
BoNT-A and all were able to stop regular use after treat-
ment with two using indomethacin as required at a fre-
quency of less than three times a month.
Headache disability scores showed a trend to improve-
ment after BoNT-A (Table 3). HIT-6 showed a median
change of 12 points (p=0.069). This is above the three-
point change suggestive of minimal clinical difference.
MIDAS improved by a median of 51 points (p =0.063).
Adverse events were reported in three subjects: one
eyebrow ptosis, one frontalis over-activity and one tran-
sient worsening in headache before improvement was
noted. All adverse events were rated as mild by patients
and transient in nature.
Discussion
This series is the largest so far of BoNT-A treatment for
HC. Five out of nine patients showed a greater than 50%
reduction in moderate or severe headache days to mild
headache days or pain free with a median reduction in
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Sex Age at
treatment
(years)
Duration of HC
at treatment
(years)
Phenotype of HC Indomethacin
dose required
to suppress HC
Co-existent
headache
Previous
number of
treatments
trialled
Reasons for administering
BoNT-A
No of
sessions
of BoNT-A
treatments
Average
units
injected
Location Autonomic
symptoms
*
Migrainous
symptoms
Ŧ
1 M 19 1 Right Yes Nil 225 mg daily EMWOA
(Bilateral)
4 Worsening EM on
Indometacin
4 168
2 F 61 1 Left Yes Yes Visual Aura 150 mg daily Nil 4 GI-upset 3 165
3 M 59 12 Right Yes Nil IM Indometacin
test**
Nil 13 Unable tolerate Indometacin;
Refractory to other treatments;
ONS in-situ
2 175
4 M 48 2 Right Yes Yes Visual Aura
(occasional)
150 mg daily EMWA (bilateral,
once month)
9 GI-upset; peptic ulcer disease;
refractory to other treatments -
awaiting ONS
2 165
5 F 47 9 Right Yes Yes 225 mg daily Past EMWOA
(stopped 2004)
3 GI-upset 5 167
6 F 49 34 Right Yes Yes 150 mg daily EMWA (bilateral,
once month)
6 GI-upset; refractory to other
treatments; ONS in-situ
2 110
7 F 48 18 Left Yes Yes IM Indometacin
test**
ISH 13 GI-upset 2 155
8 F 41 8 Right Yes No Visual Aura 150 mg daily EMWOA (side
variable/bilateral)
7 GI-upset; wheeze; dizziness;
worsening EM
6 168
9 F 54 4 Right Yes Yes 225 mg daily Nil 9 GI-upset 2 185
Mean 47 10 8 3 162
Median
(Range)
48 (19–61) 8 (1–34) 7 (3-13) 2 (2-6) 167 (110–185)
M, Male; F, Female; HC, Hemicrania continua; EMWA, Episodic migraine with aura; EMWOA, Episodic migraine without aura ISH, Idiopathic stabbing headache; BoNT-A, OnabotulinumtoxinA; GI, Gastrointenstinal; ONS,
Occipital nerve stimulator; IQR, Inter-quartile range;
*Autonomic symptoms including ptosis, lacrimation, conjunctival injection, meiosis, nasal blockage, rhinorrhea, facial redness, facial sweating, eyelid oedema,
restlessness;
ŦMigrainous symptoms including nausea, vomiting, photophobia, phonophobia, osmophobia, motion sensitivity; **IM Indometacin test blinded placebo test of 100 mg IM Indometacin v normal saline.
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7Table 2 Headache scores pre- and post- treatment with OnabotulinumtoxinA
ID Average headache days/month Average moderate -severe days/month* Average daily headache hours Average daily VRS Change in
headache
load (%)
Subjective
estimate of
response
Estimated
duration of
response
(weeks)
Pre Post Change % Pre Post Change % Pre Post Change % Pre Post Change %
1 30 0 100 20 0 100 24 0 100 5 0 100 100 >90% 16
2 30 0 100 15 0 100 24 0 100 5 0 100 100 >90% 20
3 30 30 0 30 19 37 24 24 0 8 6 25 20 30-50% 5
4 30 30 0 30 30 0 24 24 0 7 6 14 0 0 0
5 30 3 90 30 3 90 24 6 75 7 10 0 98 80-90% 12
6 30 30 0 30 23 23 15 16 0 7 6 14 0 15-25% 4
7 30 22 27 21 13 27 24 7 71 7 4 43 55 40% 6
8 30 2 93 30 0 100 24 8 67 9 2 78 99 80-90% 6
9 30 0 100 30 0 100 24 0 100 8 0 100 100 >90% 9
Mean 30 13 57 25 10 64 23 9 57 7 4 51 62 8
Median
(Range)
30 (30) 3 (0–30) 90 (0–100) 30 (15–30) 3 (0–30) 80 (0–100) 24 (15–24) 7 (0–24) 71 (0–100) 7 (5-9) 4 (0–10) 43 (0–100) 98 (0–100) 6 (0–20)
*Response defined as 50% or more improvement in average moderate-severe headache days/month; VRS, Verbal Rating Scale; Pre, Pre-treatment; Post, Post-final treatment.
M
i
l
l
e
r
e
t
a
l
.
T
h
e
J
o
u
r
n
a
l
o
f
H
e
a
d
a
c
h
e
a
n
d
P
a
i
n
 
(
2
0
1
5
)
 
1
6
:
1
9
 
P
a
g
e
4
o
f
7Table 3 Headache-associated disability scores pre- and post- treatment with OnabotulinumtoxinA
ID HIT-6 MIDAS HAD-A HAD-D
Pre Post Change
in score
Pre Post Change
in score
Pre Post Change
in score
Pre Post Change
in score
1 65 58 7 73 0 73 10 8 2 9 3 6
2 57 36 21 24 0 24 1 0 1 0 0 0
3 56 68 −12 52 52 0 3 9 −62 1 2 −10
4 68 67 1 105 130 −25 12 6 6 10 8 2
5 67 44 23 120 0 120 9 2 7 9 1 8
6 63 60 3 121 13 108 16 18 −2 1 51 50
7 63 54 9 24 13 9 2 3 −15 7 −2
8 64 62 2 240 4 236 0 0 0 3 0 3
9 76 24 52 51 0 51 12 0 12 4 0 4
Mean 64 53 12 90 24 66 7 5 2 6 5 1
Median
(Range)
64 (56–76) 58 (24–68) 7 (−12 to 52) 73 (24–240) 4 (0–130) 51 (−25 to 236) 9 (0–16) 3 (0–18) 1 (−6t o1 2 ) 5( 0 –15) 3 (0–15) 2 (−10 to 8)
HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment; HAD-A, Hospital Anxiety and Depression scale (Anxiety); HAD-D, Hospital Anxiety and Depression Scale (Depression); Pre, Pre-treatment; Post,
Post-final treatment.
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7moderate and severe days of 80%. All four subjects tak-
ing daily indomethacin prior to treatment were able to
stop regular use. Five patients reporting an 80% or more
improvement in their HC and clinically significant im-
provements were seen in both HIT-6 and MIDAS.
The patient group had tried a median of seven previ-
ous preventatives and had suffered from HC for a me-
dian of 8 years at the time of BoNT-A treatment. The
refractory nature of the group means that it is doubtful
that our observations are due to spontaneous remission.
Despite four patients reporting co-existing episodic mi-
graine, all were clearly able to differentiate this from their
HC. The phenotype of HC was secure in all subjects and all
meet ICHD-3beta criteria including a complete response
of their side-locked headache to an adequate indometacin
trial. Although a number of subjects report migrainous
symptoms associated with HC, this is an accepted feature
commented on in epidemiological studies and the ICHD-
3beta criteria [1,3]. Given that all patients were carefully
phenotyped and could clearly differentiate their episodic
migraine attacks from hemicrania continua taken together
with the sparse evidence for the efficacy of botulinum
toxin in episodic migraine, our data are consistent with a
change in HC and not the co-existent episodic migraine.
This series is still small, and this must be considered
when interpreting the results. Previous studies of BoNT-A
have reported a significant placebo response and we cannot
eliminate this as a potential confounding factor in our out-
comes. However, the relatively high response rates taken
together with the consistent efficacy of repeated BoNT-A
injections and a mean duration of effect similar to that
seen in other reports in TAC as well as chronic migraine
suggest that the response to BoNT-A in this series cannot
be attributed entirely to the placebo response [10,12,13].
The exact mechanisms by which BoNT-A produces
therapeutic benefit remains unclear, but the neurotoxin
is likely to function by multiple mechanisms, suppress-
ing events associated with peripheral and central
sensitization. Both migraine and TACs are believed to
share a common pathophysiology comprising of the acti-
vation of the trigeminovascular system and involvement
of neuroactive peptides such as calcitonin gene-related
peptide (CGRP), vasoactive peptide (VIP) and glutamate
[14]. Animal studies have provided evidence of BoNT-A
suppressing nociception in peripheral trigeminovascular
neurons and also suppressing CGRP and VIP release
from these neurons [5] There is also data to support the
hypothesis that the toxin may act via central mecha-
nisms with studies showing retrograde axonal transport
of active BoNT-A [15,16]. The potential target of BoNT-
A in chronic migraine is the direct blockage of trigemi-
nal neurons providing nociception to the head and face.
Suppression of neuro-inflammatory mediator release
leads to decreased activation of second-order neurons
within the trigemino-cervical complex and brainstem.
BoNT-A may therefore be assumed to exert its benefit by
repressing the neuro-inflammatory mediators responsible
for the maintenance of peripheral and central sensitization
[17,18]. It is therefore possible that BoNT-A has a wider
therapeutic potential than chronic migraine. It is interesting
to speculate that the clinical and functional imaging simi-
larities between migraine and HC may mean that BoNT-A
has more of an impact in HC than the other TACs which
are much more clinically distinct to migraine [19].
Conclusion
OnabotulinumtoxinA may be a promising alternative to
Indomethacin in patients with HC who do not tolerate
the drug. Treatment appears to be associated with a sig-
nificant improvement in moderate to severe headache
days and related disability. It may add another potential
therapeutic agent for HC to the limited number avail-
able. However, further controlled studies are necessary
to clarify the efficacy of BoNT-A in HC.
Competing interests
SM has received educational grants from St Jude Medical and Medtronic and
has received payment for educational presentations from Allergan. FC has
no competing interests. SL has received payment for educational sessions
from Allergan. MSM serves on the advisory board for Allergan and St Jude
Medical, and has received payment for the development of educational
presentations from Allergan, Merck Sharpe and Dohme Ltd and Medtronic.
Authors’ contributions
SM carried out data collection and analysis and drafted the manuscript. FC
helped to collect data and draft the manuscript. SL carried out data
collection and helped to draft the manuscript. MSM conceived the study,
phenotyped the patients and participated in data collection and
interpretation and revising the manuscript. All authors read and approved
the final manuscript.
Author details
1Headache Group, Institute of Neurology and The National Hospital for
Neurology and Neurosurgery Queen Square, London WC1N 3BG, UK.
2Department of Neurology, Centro Hospitalar do Porto, Oporto, Portugal.
Received: 20 January 2015 Accepted: 16 February 2015
References
1. Headache Classification Committee of the International Headache S (2013)
The International Classification of Headache Disorders, 3rd edition
(beta version). Cephalalgia 33(9):629–808, PubMed
2. Peres MF, Silberstein SD, Nahmias S, Shechter AL, Youssef I, Rozen TD et al
(2001) Hemicrania continua is not that rare. Neurology 25(6):948–951, PubMed
3. Cittadini E, Goadsby PJ (2010) Hemicrania continua: a clinical study of 39
patients with diagnostic implications. Brain 133(Pt 7):1973–1986, PubMed
Epub 2010/06/19. eng
4. Dodick DW (2004) Indomethacin-responsive headache syndromes. Curr Pain
Headache Rep 8(1):19–26, PubMed
5. Durham PL, Cady R (2011) Insights into the mechanism of
onabotulinumtoxinA in chronic migraine. Headache 51(10):1573–1577,
PubMed Pubmed Central PMCID: 3306767. Epub 2011/11/16. eng
6. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al
(2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled
results from the double-blind, randomized, placebo-controlled phases of
the PREEMPT clinical program. Headache 50(6):921–936, PubMed Epub
2010/05/22. eng
Miller et al. The Journal of Headache and Pain  (2015) 16:19  Page 6 of 77. Robbins L (2001) Botulinum Toxin A (Botox) for cluster headache: 6 cases.
Cephalalgia 21:492–503
8. Smuts JA, Barnard PWA (2000) Botulinum toxin type A in the treatment of
headache syndromes: a clinical report on 79 patients. Cephalalgia 20:332–337
9. Sostak P, Krause P, Forderreuther S, Reinisch V, Straube A (2007) Botulinum
toxin type-A therapy in cluster headache: an open study. J Headache Pain 8
(4):236–241, PubMed Epub 2007/09/29. eng
10. Freund BJ, Schwartz M (2000) The use of Botulinum toxin-A in the treatment
of refractory cluster headache: case reports. Cephalalgia 20:235–331
11. Zabalza RJ (2012) Sustained response to botulinum toxin in SUNCT
syndrome. Cephalalgia 32(11):869–872, PubMed Epub 2012/06/27. eng
12. Garza I, Cutrer FM (2010) Pain relief and persistence of dysautonomic
features in a patient with hemicrania continua responsive to botulinum
toxin type A. Cephalalgia 30(4):500–503, PubMed Epub 2009/06/12. eng
13. Khalil M, Ahmed F (2013) Hemicrania continua responsive to botulinum
toxin type a: a case report. Headache 53(5):831–833, PubMed Epub
2013/03/29. eng
14. May A, Goadsby PJ (1999) The trigeminovascular system in humans:
pathophysiologic implications for primary headache syndromes of the
neural influences on the cerebral circulation. J Cereb Blood Flow Metab
19(2):115–127, PubMed Epub 1999/02/23. eng
15. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z (2011) Behavioral and
immunohistochemical evidence for central antinociceptive activity of
botulinum toxin A. Neuroscience 186:201–207
16. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR et al (2009)
Activation of TRPV1 mediates calcitonin gene-related peptide release, which
excites trigeminal sensory neurons and is attenuated by a retargeted botulinum
toxin with anti-nociceptive potential. J Neurosci 29(15):4981–4992
17. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type
A in pain management. Headache 43(Suppl 1):S9–S15
18. Seybold VS (2009) The role of peptides in central sensitization. Handb Exp
Pharmacol 194:451–491
19. Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ
(2004) Posterior hypothalamic and brainstem activation in hemicrania
continua. Headache 44(8):747–761, PubMed Epub 2004/08/28. eng
Submit your manuscript to a 
journal and beneﬁ  t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ  eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Miller et al. The Journal of Headache and Pain  (2015) 16:19  Page 7 of 7